Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaSpax: Adipose Tissue Heterogeneity and Drug Response in Type 2 Diabetes
NCT05501483Recruiting
- Sponsor
- Karolinska Institutet
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pioglitazone, empagliflozin and semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Karolinska Institutet. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05501483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501483.